Set up in 2008, Luxembourg Bio Technologies gradually affirms its place in the world biotech field. This company particularly generates and commercializes components and chemicals for peptide synthesis, the procedure by which peptide bonds are taken shape from amino acids.

Luxembourg Bio Technologies completely opts for making use of green chemistry and sustainable methods if possible. At a similar time, a variety of its products are designed to be compatible with environmentally friendly conditions. In addition, this company always operates under the most rigorous quality assurance standards to provide the customers with the best possible products, including COMU, HDMC, OxymaPure, DEPBT, and EDC.HCL, and many others. Its services and products are being applied in a wide range of areas, such as peptide, oligonucleotide, and nanoparticle synthesis.

On top of that, many subsidiaries of Luxembourg Bio Technologies also collaborate with amenities across Europe to not only conduct laboratory-scale experiments but also multi-litre reactions for other organizations that do not own production plants to carry out their pilot projects. Simultaneously, this institution certainly pays close attention to the demands of the economy and environment to achieve optimal solutions. As a modern industrial operative, Luxembourg Bio Technologies strives to preserve and protect the environment and to consider the outcomes of the industrial field, in order to create an efficient and eco-friendly industry for generations.

Founded: 2008

Headquarters: Nes Ziona, Luxembourg
Website: https://www.luxembourg-bio.com/

The next name on the list of the largest biotech organizations in Luxembourg is Mitotech. It is a biotech company with a portfolio of novel mitochondria-targeted small molecules. Since its establishment in 2009 in Luxembourg, this company has renovated its lead compound SkQ1 for the treatment of dry eye disease in a condition where tears are unable to bring enough lubrication to the eyes. Additionally, this clinical-stage company aims to target the mitochondria to tackle neurodegenerative and metabolic disorders.

Over the years, Mitotech has witnessed the process of clinical trials for SkQ1. A phase 3 study conducted in the U.S. proved the candidate’s efficacy in decreasing the symptoms of dry eye disease in participants. In addition, the compound is also being evaluated in preclinical studies for the treatment of glaucoma, Leber’s hereditary optic neuropathy (LHON), dry age-related macular degeneration (AMD), and uveitis.

With a view to making use of the important breakthrough in delivering highly active compounds into mitochondria across a wide spectrum of neurodegenerative and metabolic indications, Mitotech promises to provide medicines based on this novel mechanism of action to patients worldwide. Simultaneously, Mitotech also aims to find out solutions to this underserved area of drug development with novel small molecules designed to target mitochondrial oxidative stress and mitochondrial lipid peroxidation.

Founded: 2009
Headquarters: Luxembourg City, Luxembourg
Website: https://www.mitotechpharma.com/

Tolerogenics is a public-private partnership venture with the Luxembourg Institute of Health (LIH), an excellent scientific hub in the field of immunology. Established in 2016, it specializes in therapies for allergies and autoimmune diseases. This Luxembourg-based biotech company has developed a tolerance-inducing allergen-specific immunotherapy setting up the function of Tregs – regulatory T cells that can suppress an immune response so as to maintain self-tolerance.

Tolerogenics is always finding out solutions to meet the medical demands for the treatment of allergies and autoimmune diseases. The current treatment options show shortcomings in the fields of safety, effectiveness and patient compliance. Therefore, it is providing a novel tolerance-based approach to enable a safe, efficient and lasting cure for allergy and autoimmune diseases with a patient-friendly treatment protocol. For the induction of tolerance, this company has developed novel and patent-protected key technologies, which can be used in combination with the established allergen, or autoantigen-specific immunotherapy or to change new treatment options.

"Cure – not only treatment of symptoms" is the main vision of Tolerogenics. It aims to become an international leading biotech company in the development of the most effective therapy options for allergy and autoimmune diseases. This company always believes in creative scientists and sophisticated management to help patients worldwide live a better life.

Founded: 2016

Headquarters: Luxembourg City, Luxembourg

Website: https://tolerogenics.lu/

Established in 2019 in Luxembourg, OrganoTherapeutics has made a remarkable contribution to the development of the biotech area. It also has received sponsorship in one round which took place in 2020, with its most recent investors being Canada-based Creative Destruction Lab (CDL) and U.S.-based startup accelerator MassChallenge.

During the operation period, OrganoTherapeutics has effectively used cutting-edge human-specific mini-brains to discover and develop a variety of valuable drug candidates targeting Parkinson’s disease. Besides that, it also screens new molecules on its proprietary human-specific mini-brains. These represent a model mimicking faithfully the human Parkinson’s disease pathology. Apparently, OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the-art 3D patient models. OrganoTherapeutics has made progress in its first own proprietary drug candidates and has access to attractive libraries for further screening.

Other than that, OrganoTherapeutics has created human-specific mini-brains, which depict the pathology of the disease in order to identify drug targets and develop candidates for the treatment of Parkinson’s disease. With a view to changing animal experiments in drug development as much as possible, the biotech’s midbrain organoids are engendered from somatic cell samples that are obtained from healthy individuals and Parkinson’s patients.

Founded: 2019

Headquarters: Luxembourg City, Luxembourg

Website: http://organo-therapeutics.com/

NIUM is a spin-off of the Luxembourg Centre for Systems Biomedicine (University of Luxembourg). The employees of this company are a strong team in which each member combines a vast track record in research and previous experience in startup and business development.

Since its founding, NIUM has paid close attention to gut health to offer high-quality related services such as microbiome and nutrition clinical analyses harnessing the technology of bioinformatics as well as conducting in vitro experiments to predict the impact of certain foods on the gut. On top of that, the company has constantly developed gut-on-a-chip models which mimic interactions between microbes and the gut. These chips are given to a stool sample, and after about 48 hours, the composition of the microbiome is examined. In addition, NIUM jointly cooperates with food companies to assign probiotic scores to products. After that, these food companies decide whether they want to go ahead with the development of their products.

In collaboration with Arizona State University College of Health Solutions, AZ WearTech Center and Aventyn in the U.S., NIUM is carrying out a pilot nutrition support study for ambulatory cancer patients. At a similar time, the biotech company has also partnered with the Luxembourg Institute of Health to investigate how incorporating fibres in people's diets affects specific gut bacteria.

Founded: 2019

Headquarters: Esch-sur-Alzette, Esch-sur-Alzette

Website: https://www.nium.io/

Luxbiotech is a Luxembourg biotechnology company that offers phycocyanin compounds. During its operation, this company effectively makes a contribution to the development of Luxembourg's biotech market and gradually becomes an important organization in the biotech system of this nation. As a biotech company that offers phycocyanin compounds, Luxbiotech is actively using five technologies for its website, according to BuiltWith, such as Apache, CrUX Dataset, and CrUX Top 50m.

Inspired by nature’s circularity, Luxbiotech creates the most powerful and exclusive bioactive from microalgae. The institution manufactures high-quality nutritional and skincare products that improve well-being as well as protect the environment. One of the remarkable things about Luxbiotech is that expertise uses technology to recreate the conditions of certain microalgae ecosystems to obtain the purest and highest quality bioactive. Thanks to this, their patented photobioreactors are the only ones capable of recreating the conditions of AFA’s natural environment to guarantee its maximum level of purity. Simultaneously, this is the first and the only organization in the world that has achieved a better-cultivated product than those that can be obtained in the original lake.

Taking advantage of the potential of microalgae that grow in marine ecosystems, Luxbiotech promises to develop a series of skincare and nutritional products to bring high-quality services and products to their customer in the long term.

Founded: 2007

Headquarters: Luxembourg City, Luxembourg

Website: https://www.luxbiotech.com/